SCHEMBL5485414

SCHEMBL5485414

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3sccc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
LMNA P02545 4/20 0.39
ELANE P08246 1/20 0.39
HSD17B10 Q99714 4/20 0.38
RAB9A P51151 3/20 0.38
POLB P06746 2/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
GLA P06280 1/20 0.35
HTT P42858 2/20 0.35
CNR1 P21554 1/20 0.35
GPR35 Q9HC97 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
KIF11 P52732 1/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482736 0.78 MAPT (0.56) MAPTLMNAELANEHSD17B10RAB9A
Oxyphenisatin Acetate SCHEMBL7528210 0.75 MAPT (1.00) MAPTLMNAELANESMN1; SMN2MEN1
Oxyphenisatin Acetate SCHEMBL29737232 0.75 MAPT (1.00) MAPTLMNAELANESMN1; SMN2MEN1
Oxyphenisatin Acetate SCHEMBL555117 0.75 MAPT (1.00) MAPTLMNAELANESMN1; SMN2MEN1
SCHEMBL5481283 0.73 MAPT (0.60) MAPTLMNAELANEHSD17B10RAB9A
SCHEMBL5483660 0.72 MAPT (0.70) MAPTLMNAPOLBSMN1; SMN2MEN1
SCHEMBL30226150 0.72 MAPT (0.70) MAPTLMNAELANEHSD17B10POLB
SCHEMBL5482053 0.70 MAPT (0.56) MAPTLMNAELANEHSD17B10POLB
SCHEMBL5482321 0.70 MAPT (0.60) MAPTLMNAELANEHSD17B10RAB9A
SCHEMBL11748297 0.70 MAPT (0.88) MAPTLMNAELANESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885LMNA 3104/4885ELANE 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.